Inventiv clinical trial recruitment solutions

We would like to take this opportunity to thank you for your business and would greatly appreciate your continued support in the future. Le contenu ci-dessous est disponible uniquement en anglais. Clinical Development Our fit-for-purpose CRO solutions are tailored to your product and requirements. Commercialization We improve brand performance by leveraging data and insights and deep therapeutic expertise.

Consulting Our consulting practitioners span the entire product development and delivery continuum. Learn About Our Solutions. Therapeutic Areas Discover More. Cross-Functional Solutions Discover More. Learn About Our Therapeutic Expertise.

Accelerating Your Success Decentralized Solutions Consultative problem-solving to address the unique nuances of your trial. ViS' collaborative analytics approach integrates large amounts of data to provide up-to-date analytics, while enabling research centers to securely and efficiently showcase their disease-specific capabilities to trial planners. Under the partnership agreement, and building upon ViS research platform, iCTRS and ViS will co-develop advanced, proprietary features for the platform that include automation of the Confidential Disclosure Agreement workflow and final sign-off, and enhanced analytical capabilities to rapidly compare feasibility information between sites.

In 40 countries around the world, inVentiv's 12, employees work with more than pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. Lee Partners, L. ViS helps these investigative sites by decreasing their administrative burden related to feasibility questionnaires, while enabling them to efficiently display their disease-specific capabilities, at no cost.

The end result is that optimal decisions can be reached using a small fraction of the time and cost incurred through conventional methods. The ViS Research Institute was created as a global enterprise in , with trial planning experts in four continents. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially.

These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions.